CAPITAL STOCK (Schedule of Summary of Equity Awards other than Options Activity) (Details) - $ / shares	12 Months Ended
	Mar. 28, 2026	Mar. 29, 2025	Mar. 30, 2024	Apr. 01, 2023
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward]
Shares, Beginning Balance (in shares)	303,003
Shares, Granted (in shares)	225,738
Shares, Vested (in shares)	(157,290)
Shares, Forfeited (in shares)	(41,633)
Shares, Ending Balance (in shares)	329,818	303,003
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]
Weighted Average Grant Date Fair Value (in dollars per share), Beginning Balance	$ 81.27
Weighted Average Grant Date Fair Value (in dollars per share), Granted	70.52	$ 95.09	$ 89.21
Weighted Average Grant Date Fair Value (in dollars per share), Vested	78.36	75.04	67.14
Weighted Average Grant Date Fair Value (in dollars per share), Forfeited	78.15
Weighted Average Grant Date Fair Value (in dollars per share), Ending Balance	$ 75.69	$ 81.27
Restricted Stock Units (RSUs) \| Minimum \| Employees
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]
Award vesting period	3 years
Performance Share Units (PSUs)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward]
Shares, Beginning Balance (in shares)	335,843
Shares, Granted (in shares)	220,349			35,443
Performance shares target, percentage	100.00%
Shares, Vested (in shares)	(162,066)
Shares, Forfeited (in shares)	(36,495)
Shares, Ending Balance (in shares)	357,631	335,843
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]
Weighted Average Grant Date Fair Value (in dollars per share), Beginning Balance	$ 112.10
Weighted Average Grant Date Fair Value (in dollars per share), Granted	87.66	$ 128.25	128.83
Weighted Average Grant Date Fair Value (in dollars per share), Vested	84.96	72.35	$ 0
Weighted Average Grant Date Fair Value (in dollars per share), Forfeited	114.24
Weighted Average Grant Date Fair Value (in dollars per share), Ending Balance	$ 108.86	$ 112.10
Performance Share Units (PSUs) \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward]
Performance shares target, percentage	0.00%
Performance Period One \| Performance Share Units (PSUs)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward]
Performance shares target, percentage	128.00%
Shares, Vested (in shares)	(162,066)

HAEMONETICS CORP 10-K